A randomized, multicenter, double-blind study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with dyspareunia as the most bothersome symptom Article

sustainable development goals

authors

publication date

  • February 1, 2018

webpage

published in

keywords

  • Dyspareunia
  • Genitourinary syndrome of menopause
  • Vaginal estrogen
  • Vulvovaginal atrophy

start page

  • 133

end page

  • 138

volume

  • 25

issue

  • 2